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We examined the effect of a controlled diet and two probiotic
preparations on urinary oxalate excretion, a risk factor for
calcium oxalate kidney stone formation, in patients with mild
hyperoxaluria. Patients were randomized to a placebo, a
probiotic, or a synbiotic preparation. This tested whether
these probiotic preparations can increase oxalate metabolism
in the intestine and/or decrease oxalate absorption from the
gut. Patients were maintained on a controlled diet to remove
the confounding variable of differing oxalate intake from
food. Urinary oxalate excretion and calcium oxalate
supersaturation on the controlled diet were significantly
lower compared with baseline on a free-choice diet. Neither
study preparation reduced urinary oxalate excretion nor
calcium oxalate supersaturation. Fecal lactobacilli colony
counts increased on both preparations, whereas enterococcal
and yeast colony counts were increased on the synbiotic.
Total urine volume and the excretion of oxalate and calcium
were all strong independent determinants of urinary calcium
oxalate supersaturation. Hence, dietary oxalate restriction
reduced urinary oxalate excretion, but the tested probiotics
did not influence urinary oxalate levels in patients on a
restricted oxalate diet. However, this study suggests that
dietary oxalate restriction is useful for kidney stone
prevention.
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The formation of calcium oxalate (CaOx) kidney stones is
extremely common,1 and evidence suggests that minimal,
perhaps transient, elevations in urinary oxalate concentration
may be important factors in at least a subgroup of these
patients with ‘idiopathic’ CaOx urolithiasis.2 In the case of
enteric hyperoxaluria, the pathogenic role of oxalate is clear,
and renal scarring can also be observed as a consequence of
oxalate exposure and CaOx crystal deposition.3–6 Unfor-
tunately, few satisfactory specific treatments for hyperoxaluria
are available. Dietary restriction is commonly advised, but
is difficult for patients to follow effectively without extensive
education, in part because oxalate content is not listed on
food labels.7 Typical treatment strategies for enteric hyper-
oxaluria also include low-fat diets to limit malabsorption and
effects of fatty acids and bile acids on oxalate absorption in
the distal colon,8,9 oral calcium to bind oxalate,10 and bile
acid sequestrants such as cholestyramine.8,11 These more
intensive strategies have not been widely employed for
patients with CaOx stones and, even if effective, they do
not seem likely to be accepted by the majority of patients
with mild hyperoxaluria and idiopathic CaOx stone disease.
Previous studies have shown that components of the
endogenous digestive microbiota can utilize oxalate, poten-
tially limiting its absorption from the intestinal lumen.12 A
recent preliminary study demonstrated that a preparation of
lactic acid bacteria degraded oxalate in vitro and reduced
urinary oxalate excretion when given by mouth.13 We
previously demonstrated that the same preparation of lactic
acid bacilli (Oxadrop, VSL Pharmaceuticals, Gaithersburg,
MD, USA) can reduce urinary oxalate excretion in patients
with enteric hyperoxaluria.14 Agri-King Synbiotic (AKSB) is a
candidate synbiotic preparation extensively studied at Mayo
Clinic that might have beneficial effects on gastrointestinal
health, although there is no evidence it should influence
oxalate metabolism directly. In this study, we tested the effect
of these two preparations on oxalate excretion in subjects
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with mild hyperoxaluria. Our hypothesis was that such
preparations can increase oxalate metabolism in the intestine,
and/or decrease gastrointestinal oxalate absorption from the
gut and reduce oxalate elimination in the urine. Importantly,
subjects were maintained on a controlled diet while
conducting the urinary oxalate measurements, to remove
the potential confounding variable of differing amounts of
dietary oxalate intake from food.
RESULTS
Baseline characteristics of the subjects are listed in Table 1. There
were 36 men and 4 women of a mean age of 53±14 years who
had passed or had 2.24±1.84 stones (median 2.0) removed.
Demographic characteristics did not vary between groups.
The controlled metabolic diet was well tolerated by the
study group. Table 2 contains baseline 24-h urinary
parameters for all subjects regardless of group on the free-
choice diet (pre-study) and those on the controlled metabolic
diet at time zero. Urinary sodium fell, as expected, to
123±38 mEq/day, thus confirming compliance with the
controlled metabolic diet, whereas urinary creatinine,
volume, and calcium did not change. Urinary oxalate fell
significantly from 0.45±0.12 to 0.29±0.09 mmol/l/day, as
did CaOx and brushite supersaturation (SS), whereas uric
acid SS increased slightly. Figure 1 demonstrates the
significant fall in urinary oxalate excretion and CaOx SS
values for most subjects between baseline and time zero, as
well as for the overall mean. Conversely, 24-h urinary
calcium, citrate, and volume excretion did not change.
Table 3 lists time zero and final urinary chemistries for the
three study groups by preparation. There was no further
improvement in any urinary parameter on either of the study
drug. In particular, neither urinary oxalate nor CaOx SS fell
from the time zero values (Figure 2).
Stool colony counts for lactobacilli increased among
subjects on AKSB and Oxadrop (Table 4). Fecal enterococcal
colony counts also increased in those on AKSB. No changes in
fecal flora occurred in those on placebo, and baseline colony
counts also did not differ between groups. Exact confirmation
of the presence or numbers of specific microorganism strains
by PCR was not attempted. Among 21 patients with both pre-
and post-stool culture data, changes in urinary oxalate level
did not significantly correlate with changes in fecal lactoba-
cillus, enterococcal, or yeast colony number, although power
to detect this association was limited.
Urinary oxalate (Po0.001, r¼ 0.38) and calcium
(Po0.001, r¼ 0.36) showed significant positive correlations
with CaOx SS, whereas urine volume was negatively
correlated (Po0.0001, r¼0.56). Conversely, urinary citrate
was not significantly correlated (P¼ 0.15, r¼ 0.16). In a
multiple regression model (adjusting for diet and repeated
readings), urinary CaOx SS was positively associated with
oxalate (Po0.001) and calcium (Po0.001) levels, and
negatively associated with urine volume (Po0.001) and log
citrate levels (P¼ 0.008) (Table 5). Among these factors,
urine volume and calcium had the most significant effects.
On the basis of the model slopes (and assuming other
predictors remain fixed), an increase from the 25 to 75th
percentile in urine volume or citrate would be projected to
decrease CaOx SS by 0.57 and 0.068 delta Gibbs (DG),
Table 1 | Patient characteristics
Placebo AKSB Oxadrop Total
Number 14 12 14 40
Male: female 12:2 10:2 14:0 36:4
Age (mean±s.d.) 50±13 55±18 53±15 53±14
Stones passed (mean; median) 2.5; 2.0 2.36; 1.0 1.86; 2.0 2.24; 2.0
Abbreviation: AKSB, Agri-King Synbiotic.
Table 2 | Summary of urinary values for 40 idiopathic CaOx stone patients at baseline on free-choice diet and at time zero after
1 week on a controlled low-oxalate diet
Urine parameter Baseline (free-choice diet) Time zero (controlled diet) P-valuea
Oxalate (mmol/l) 0.45 (0.12) 0.29 (0.09) o0.0001
ss CaOx (DG) 1.69 (0.52) 1.34 (0.61) 0.0007
Volume (ml) 2288 (692) 2223 (644) 0.56
Osmolality (mOsm/kg) 521 (205) 483 (191) 0.15
Calcium (mg) 231 (92) 244 (93) 0.44
Citrate (mg) 849 (570) 695 (460) 0.0054
pH 6.08 (0.83) 5.92 (0.40) 0.20
Uric acid (mg) 770 (265) 725 (224) 0.32
Sodium (mEq) 214 (69) 121 (34) o0.001
Chloride (mEq) 199 (70) 109 (28) o0.001
Potassium (mEq) 81 (25) 76 (20) 0.22
Magnesium (mg) 144 (60) 133 (38) 0.15
Sulfate (mEq) 26 (8) 34 (7) o0.001
Phosphorous (mg) 1203 (435) 1079 (253) 0.11
ss BR (DG) 0.06 (1.19) 0.51 (1.05) 0.04
ss Uric acid 0.37 (2.77) 0.86 (2.26) 0.02
Creatinine (mg) 1944 (503) 1833 (446) 0.15
Abbreviations: BR, brushite; CaOx, calcium oxalate; DG, delta Gibbs; SS, supersaturation.
aPaired t-test comparing time zero with baseline.
Values are given as mean (s.d.).
Values in bold were significantly different on controlled diet.
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respectively. Similarly, decreases in calcium and oxalate from
the 75th to 25th percentile led to decreases of 0.50 and 0.30
DG in CaOx SS, respectively. A regression model predicting
change in CaOx SS (from time zero to final) as a function of
changes in oxalate, calcium, volume, and citrate resulted in
similar significant associations for all four parameters
(Table 6).
Two subjects (one on placebo, one on Oxadrop) dropped
out within the first week because of demands of the study
diet and protocol. The 24-h urine samples for the second
visits were lost for one subject (placebo) and there was a
protocol error in another (insufficient quantity of AKSB
supplied). One patient on Oxadrop reported diarrhea and
did not complete the protocol. As urine values for the final
visit were not available for five subjects, they were not
included in analyses regarding the effect of the study
preparations on urine oxalate levels. One patient on placebo
reported cramps and mild diarrhea, but did complete the
study and was included.
DISCUSSION
Our current study provides evidence that a controlled
metabolic diet, low in oxalate and moderate in content of
calcium, protein, and sodium, can reduce urinary oxalate
excretion and CaOx SS. Therefore, these data strongly
support the key role of diet as a determinant of urinary
oxalate excretion and CaOx SS. Addition of either of two
probiotic combinations (AKSB, Oxadrop) in an effort to
enhance intraintestinal oxalate metabolism or decrease
oxalate absorption from the gut did not augment the effect
of controlled metabolic diet alone. The relative significance of
net intestinal oxalate absorption as a determinant of urinary
oxalate excretion and the potential for use of agents to
modify these processes, remain to be established.
The importance of the urinary composition in the
pathogenesis of stone disease is suggested by the observation
that urinary SS predicts stone composition15 and that oxalate
concentration is a critical determinant of SS.16 To date, all
successful kidney stone treatment trials have employed
strategies to directly reduce the urinary excretion of elements
that might influence SS, such as thiazide diuretics to decrease
urinary calcium,17 allopurinol to decrease urinary uric acid,18
and a diet with increased calcium and reduced protein, sodium,
and oxalate content designed to have multiple complementary
effects on urinary SS.19 However, no treatment trial has directly
shown that reducing urinary oxalate will change stone
formation rates, largely because no strategy other than diet is
currently available to reduce urinary oxalate excretion.
Mild hyperoxaluria is commonly observed in CaOx stone
patients.16 In normal urine, the ratio of calcium to oxalate is
usually X5:1 (calcium to oxalate). As the stoichiometric
relationship between calcium and oxalate in CaOx crystals is
1:1, and as the greatest crystalline mass is produced when
they are closest to equimolar concentrations, increases in
urinary oxalate should have a greater influence on crystalline
mass than increases in calcium.2 Furthermore, in the normal
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Figure 1 |Changes in urinary oxalate on a free-choice diet compared with a controlled metabolic low-oxalate diet. Urine oxalate
(a) and CaOx SS (b) values fell on the controlled metabolic diet for the majority of subjects. Other key determinants of SS, including
urinary calcium excretion (c), citrate excretion (d), and urine volume (e), did not change. *Po0.001 time zero versus baseline. CaOx,
calcium oxalate; SS, supersaturation.
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urinary range small changes in oxalate concentration
influence CaOx SS, with respect to CaOx far more than
changes in calcium concentrations.16 These predictions are
supported by in vitro studies performed in urine, as it is easy
to initiate CaOx crystallization by addition of oxalate, but
difficult to do so by adding excess calcium.20 Our analysis of
urine chemistries from stone-forming patients suggested that
changes in urinary calcium and oxalate had roughly similar
effects on CaOx SS (Tables 5, 6). Therefore, all lines of
evidence suggest that changes in urinary oxalate can have
important effects on urinary CaOx SS, at least equal to that of
the other key analytes, calcium and citrate.
It has been estimated that on a typical Western diet, only
B10% of ingested oxalate is absorbed, and this is thought
to constituteB1/3 of the total oxalate in the urine, the other
2/3 being synthesized by the liver.21 However, these estimates
may not be accurate. In an intriguing study, two normal
individuals were placed on a rigorously defined, essentially
oxalate-free diet, and urinary oxalate excretions fell from
normal levels (mean 19.5 mg/day) to very low levels within a
week (7 mg/day).22 Urinary oxalate excretion promptly rose
after a normal diet was resumed. Therefore, a larger
percentage of urinary oxalate may arise from diet than is
traditionally assumed. As a consequence, factors that mediate
oxalate absorption from food might critically influence
urinary oxalate levels, independent of dietary oxalate intake.
Recent studies support the hypothesis that increased
gastrointestinal absorption of oxalate could mediate hyper-
oxaluria in a subgroup of CaOx stone formers. When a
standard oxalate load was administered to 60 CaOx stone
formers, those with mild hyperoxaluria at baseline (n¼ 21)
responded with a significantly greater peak in urinary oxalate
excretion 4 h later.23 Utilizing a standardized protocol to
Table 3 | Summary of urinary values for 35 idiopathic CaOx stone patients randomized to placebo, AKSB, or Oxadrop
Placebo (n=12) AKSB (n=10) Oxadrop (n=13)
Urine parameter Time zero Final P-valuea Time zero Final P-valuea Time zero Final P-valuea P-valueb
Oxalate (mmol/l) 0.28 (0.07) 0.30 (0.10) 0.18 0.29 (0.07) 0.28 (0.07) 0.56 0.28 (0.10) 0.31 (0.09) 0.07 0.14
ss CaOx (DG) 1.19 (0.56) 1.40 (0.65) 0.045 1.49 (0.69) 1.42 (0.49) 0.67 1.22 (0.57) 1.36 (0.67) 0.23 0.30
Volume (ml) 2437 (676) 2256 (632) 0.12 1987 (620) 2001 (761) 0.94 2305 (632) 2265 (858) 0.79 0.60
Osmolality (mOsm/kg) 419 (148) 468 (156) 0.11 543 (239) 495 (202) 0.42 478 (173) 511 (205) 0.28 0.20
Calcium (mg) 235 (55) 256 (68) 0.09 265 (153) 238 (121) 0.39 244 (77) 228 (64) 0.08 0.07
Citrate (mg) 738 (422) 774 (583) 0.62 737 (365) 669 (239) 0.49 768 (564) 776 (638) 0.83 0.96
pH 5.86 (0.30) 5.90 (0.43) 0.70 6.19 (0.44) 6.32 (0.60) 0.10 5.92 (0.36) 5.90 (0.36) 0.78 0.13
Uric acid (mg) 774 (225) 745 (198) 0.51 652 (199) 642 (182) 0.92 790 (157) 771 (157) 0.58 0.59
Sodium (mEq) 111 (39) 122 (24) 0.32 131 (43) 112 (31) 0.16 124 (34) 120 (33) 0.48 0.07
Chloride (mEq) 99 (30) 107 (20) 0.36 113 (39) 96 (27) 0.15 115 (18) 118 (31) 0.66 0.19
Potassium (mEq) 73 (18) 75 (17) 0.79 81 (28) 72 (18) 0.26 80 (17) 89 (22) 0.06 0.25
Magnesium (mg) 137 (53) 140 (50) 0.50 140 (34) 133 (35) 0.51 132 (28) 128 (25) 0.46 0.63
Sulfate (mEq) 34 (6) 33 (5) 0.29 32 (11) 31 (10) 0.49 35 (6) 35 (8) 0.82 0.77
Phosphorous (mg) 1106 (240) 1088 (220) 0.74 1023 (349) 935 (265) 0.38 1103 (172) 1153 (258) 0.40 0.89
ss BR (DG) 0.78 (1.18) 0.48 (1.13) 0.13 0.11 (0.70) 0.18 (0.61) 0.72 0.51 (1.05) 0.55 (1.15) 0.85 0.20
ss Uric acid 1.07 (1.95) 1.23 (1.90) 0.78 0.22 (3.01) 0.95 (3.72) 0.35 1.15 (2.11) 1.36 (2.39) 0.06 0.43
Creatinine (mg) 1815 (488) 1756 (524) 0.44 1788 (582) 1545 (389) 0.17 1909 (369) 1929 (420) 0.80 0.75
Abbreviations: AKSB, Agri-King Synbiotic; BR, brushite; CaOx, calcium oxalate; DG, delta Gibbs; SS, supersaturation.
aP-value from signed-rank test that shows mean within group change is zero.
bP-value from Kruskal–Wallis test of equal change across groups.
No improvements in key urinary parameters were observed in any group before (time zero) or after 4 weeks treatment (final). Values are given as mean (s.d.).
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Figure 2 |Changes in urine composition while on AKSB and
Oxadrop compared with placebo. Urine oxalate (a) and CaOx SS
(b) did not change after 4 weeks on either study drug or placebo.
CaOx, calcium oxalate; SS, supersaturation. AKSB, Agri-King Synbiotic.
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measure intestinal absorption and urinary excretion of
[13C2]oxalate, Hesse et al.
24 found that, as a group, both
male and female CaOx stone formers absorbed a greater
percentage of the oxalate load (9.45 versus 6.61% for males
and 8.07 versus 6.86% for females; both Po0.01). Multiple
older studies also support the hypothesis that CaOx stone
formers, as a group, tend to overabsorb oxalate from their
diet.25–27 Furthermore, two recent studies suggest that dietary
instructions can effectively reduce urinary oxalate levels in a
stone clinic setting.28,29
Factors that are known to influence availability of oxalate
for absorption include the availability of free calcium and
magnesium ions that can complex with oxalate and decrease
its rate of absorption, and the presence of free fatty acids in
the distal colon, which can form soaps with calcium and
thereby increase concentration of free oxalate.30 The presence
or absence of colonization with oxalate-degrading bacteria
(Oxalobacter formigenes) may also be important.31 As a
portion of an oxalate load appears in the urine within hours
after ingestion, it is assumed that some can be absorbed in
the proximal intestine.32 However, during disease states
associated with fat malabsorption and enteric hyperoxaluria,
it is clear that a majority of oxalate overabsorption occurs in
the colon,33 and is thought to be passive and paracellular.30
In the absence of fat malabsorption, there is evidence
that specific energy-dependent transporters might mediate
both net oxalate absorption, as well as oxalate secretion.34
The latter might be particularly critical in eliminating excess
oxalate when renal function is reduced.35 The relative
importance of these mechanisms to intestinal oxalate
transport in healthy individuals, compared with mildly
hyperoxaluric stone formers, remains unclear.
Generally, as is the case for Oxadrop, probiotics are viable
preparations of commensal microorganisms useful for the
control or inhibition of pathogens in the digestive tract while
promoting the establishment of the normal beneficial
microbiota.36–38 The mixture of organisms in Oxadrop were
also selected for their ability to degrade oxalate in vitro.13 A
prebiotic is a food ingredient that is not digestible and can
benefit the patient by aiding the growth of intestinal
bacteria.37,38 Synbiotics, such as AKSB, are a combination
of prebiotic and a probiotic. This product uniquely contains
both bacteria and yeast, whereas most products contain one
or the other; the bacteria and yeast are viable, and the
Table 4 | Quantitative stool cultures before and after administration of study drug
Placebo (n=10) AKSB (n=8) Oxadrop (n=11)
Stool organism
(microbes per gram dry stool) Time zero Final P-valuea Time zero Final P-valuea Time zero Final P-valuea
MRS Lactobacilli ( 106) 9.08 (11.03) 12.30 (13.42) 0.58 2.75 (2.04) 193.98 (306.94) 0.02 24.09 (41.24) 53.03 (48.93) 0.04
KF Enterococci ( 106) 0.29 (0.43) 1.10 (2.11) 0.68 0.13 (0.26) 124.66 (287.10) 0.002 13.32 (31.30) 4.15 (8.22) 0.28
PDA Yeast ( 103) 0.32 (0.54) 0.74 (1.46) 0.89 NA 55.10 (91.84) NA 34.95 (66.18) 37.73 (92.12) 0.77
Abbreviations: AKSB, Agri-King Synbiotic; KF, streptococcus medium (supplemented with 2,3,5-triphenyl-2H-tetrazolium chloride for increased selectivity of enterococci);
MRS, lactobacilli deMan–Rogosa–Sharpe medium (supplemented with amphotericin B for suppression of fungal contamination); NA, not applicable; PDA, potato dextrose agar
(supplemented with tartaric acid for suppression of bacterial contamination).
aComparison between time zero and final.
Values are given as mean (s.d.).
Table 5 |Multivariate predictors of CaOx SS (Y)a
Predictor (X)
25th, 75th
Percentile of X Slope (s.e.) P-value
Predicted change in CaOx SS (Y) with
independent increase in X
from 25 to 75th percentile
Predicted change in Y
relative
to median (1.69), %
Intercept — 2.52 (0.40) — — —
Oxalate (mmol/l) 0.37, 0.52 1.99 (0.44) o0.0001 0.30 18
Volume (ml) 1839, 2794 0.0006 (0.0001) o0.0001 0.57 34
Calcium (mg) 165, 317 0.0033 (0.0004) o0.0001 0.50 30
Citrate (loge, mg) 6.43, 6.83 0.1690 (0.0634) 0.0077 0.068 4.0
Post-diet visit (1=yes, 0=no) — 0.15 (0.0558) 0.0074 — —
Abbreviations: CaOx, calcium oxalate; SS, supersaturation.
aMultiple regression analysis (generalized estimating equations model) based on 80 readings in 40 patients.
Table 6 |Multivariate predictors of change in CaOx SS from
baseline to time zeroa
Predictor Slope (s.e.) P-value
Intercept 0.15 (0.09) —
Change in oxalate (mmol/l) 2.01 (0.48) 0.0002
Change in urine volume (ml) 0.00051 (0.00008) o0.0001
Change in calcium (mg) 0.0024 (0.0005) o0.0001
Change in citrate (mg) 0.00057 (0.00017) 0.0018
Abbreviations: CaOx, calcium oxalate; SS, supersaturation.
aMultiple regression analysis based on 40 patients. Positive changes imply
an increase.
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fructooligosaccharide provides an active growth substrate
that is indigestible by the subject and preferentially used by
Enterococcus faecium in AKSB (as opposed to gut pathogens).
Although there are no published data in humans supporting the
efficacy of AKSB, the preparation SF68, which is widely used in
Europe, contains a key component (E. faecium) and appears to
decrease rates of antibiotic-associated diarrhea.39 There are
no data to suggest that components in AKSB can degrade
oxalate, and it was used in this study to determine whether a
preparation that has been used to promote overall gastro-
intestinal health might nonspecifically alter oxalate metabolism
or absorption. Oxadrop, on the other hand, also appears to
directly metabolize oxalate, at least to a modest degree.13
Despite these potential beneficial effects of the probiotic
and synbiotic preparation on oxalate absorption from the
gut, we did not demonstrate any effect of either preparation
in this study in subjects on a controlled metabolic low-
oxalate diet. Although the number of subjects in each group
was modest, there was no indication of positive effect in the
conditions tested. Therefore, we do not think including more
subjects in this exact protocol would have altered results. In a
previous study of the same probiotic preparation in patients
with enteric hyperoxaluria, we did find a modest reduction in
net urinary oxalate excretion.14 However, unlike this study,
the previous one was not randomized or placebo-controlled,
and the participants had clear evidence for enteric hyperox-
aluria. It is unknown whether AKSB or Oxadrop might have
had an effect in the current population if the subjects had
been studied on a higher oxalate diet, or even a free-choice
diet. For example, it is possible that the low-oxalate diet
prevented adequate gastrointestinal growth and activity of
the oxalate-degrading bacteria in Oxadrop, as has been
observed in animal studies with O. formigenes.40 However, a
previous small crossover study of Oxadrop in patients with
idiopathic CaOx stones and mild hyperoxaluria on a free-
choice diet also failed to demonstrate an effect.41 It is also
possible that the relatively short period of time on the
controlled diet altered the equilibrium of the gastrointestinal
tract flora, and that longer-term studies might demonstrate a
more dramatic effect.
This study supplements evidence in the literature that diet
is an effective tool to reduce urinary oxalate excretion
Furthermore, analysis of the data confirms that urinary
oxalate intake is an independent determinant of urinary
CaOx excretion. The strength of this protocol was the use of
exactly defined diets prepared in a Clinical Research Unit.
Although one could question the practicality of advocating a
low-oxalate diet for long-term management, two recent
studies in an outpatient stone clinic setting confirmed that
effective dietary counseling can reduce urinary oxalate
excretion.28,29 A third study demonstrated successful com-
pliance with a low-sodium diet that secondarily reduced
urinary calcium.42 Therefore, amongst idiopathic CaOx stone
formers, efforts should be directed toward improved
strategies to educate patients in order to improve compliance
with a stone prevention diet that includes low sodium,
normal calcium, reduced oxalate, and increased fluid intake.
Furthermore, a controlled trial to demonstrate the effect of
such a diet on stone formation rates seems warranted.
METHODS
This double-blind, placebo-controlled study was approved by the
Mayo Clinic Institutional Review Board and registered with the
United States National Library of Medicine (NCT 00587041;
www.clinicaltrials.gov).
Oxadrop
Each gram of the mix (Oxadrop) contains 2 1011 bacteria
(Lactobacillus acidophilus, L. brevis, Streptococcus thermophilus, and
Bifidobacterium infantis). The different strains are mixed in a 1:1:4:4
weight and prepared as a granulate. The organisms were chosen on
the basis of their ability to degrade oxalate in vitro, and Oxadrop is
different than the more widely studied VSL#3,43 which contains
three of the above four bacterial species with the exception of
L. brevis, as well as three other species of lactobacillus and two other
species of bifidobacteria. In clinical trials performed with Oxa-
drop,13 there have been no adverse events noted, and no case of
clinical infection has been traced to ingested probiotic lactic acid
bacteria in a normal host.44
AKSB
AKSB ingredients were mixed into powder and provided to Mayo
clinic, where it was encapsulated by the Mayo Research Pharmacy.
Each AKSB capsule contains the following active ingredients (subjects
were given two AKSB capsules per day for a total of 1010 organisms):
(1) Fructooligosaccharide (115 mg), manufactured as Ultra-FOS ST
by Encore Technologies, Minnetonka, MN, as food-grade quality and
is a prebiotic component of AKSB; (2) E. faecium (E. faecium SF68;
4.5 billion) produced by Cerbios-Pharma SA (Barbengo, Switzerland);
(3) Saccharomyces cerevisiae subsp. boulardi (300 million), a yeast
produced as LEVUCELL SB by Lallemand Biochem International,
Ontario, Canada, as ‘food-grade’ quality; and (4) S. cerevisiae (200
million), a food-grade yeast produced as active dry yeast by SAF
(USA) Corporation in Milwaukee, WI. AKSB was developed by
Agri-King (Fulton, IL, USA), with the primary aim of improving gut
performance in animals so that the routine use of antibiotics in
animal feeds could be reduced or eliminated. Studies by Agri-King.
have confirmed that the preparation improves intestinal health and
reduces the risk of illness when animals fed with the preparation are
challenged with food- or water-borne pathogens, and improves
overall animal growth rates.
Study population
Subjects were identified as those who had CaOx nephrolithiasis and
mild hyperoxaluria of unknown etiology (40.35 mmol/l/day)
between May 2006 and May 2009. Stone disease was defined as
the presence of radio-opaque stones on X-ray, or a history consistent
with passage of a stone, or stone surgery, or extracorporeal shock
wave lithotripsy in the last 5 years. Stone composition could be
confirmed either by stone analysis demonstrating composition
X50% CaOx or by radiographic demonstration of a calcific renal
stone in the presence of hyperoxaluria. Inclusion criteria allowed
subjects taking drugs for the prevention of stone disease, including
pyridoxine, thiazides, citrate supplements, and allopurinol, as long
as there was no change in these medications for at least three
previous months and during the study, and hyperoxaluria was
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present. Study subjects were selected from among those who carried
out 24-h collections for routine clinical purposes in the Mayo renal
stone clinic. Subjects were excluded if they were on immunosup-
pressive medications (excluding small stable doses of prednisone of
p10 mg), had human immunodeficiency virus infection, known
enteric bacterial infection, or a history of splenectomy; had a current
malignancy other than superficial skin cancers that had been excised
or were felt to be in complete remission (45 years); had previous
colectomy; or had completed a course of oral or parenteral
antibiotics o2 weeks before initiation of the study. Subjects who
required a course of antibiotics during the period of preparation
administration were withdrawn from the study and excluded from
the final analysis. Subjects were also told to avoid probiotic
preparations or dairy products containing live cultures.
Study design
Baseline urine collection was the most recent 24-h urine study
available that was used to qualify subjects for the study, and was
obtained on free-choice diet as per clinical routine (Figure 3). Eligible
subjects were then placed on a constant metabolic diet to eliminate
oxalate intake as a variable. The diet contained reduced oxalate
(80–100 mg), normal calcium (1000 mg), adequate protein (15% of
total calories), low fat (25% of total calories), vitamin C
(100–150 mg), and moderate sodium (120–150 mEq). Calorie intake
was calculated to avoid weight loss. Controlled metabolic diet
contents were calculated using ProNutra nutritional analysis software
(Viocare Technologies, Princeton, NJ, USA, Version 3.1.0.13.,
Copyright(C) 2002). Diets were individualized to allow for food
allergies and intolerances, but remained constant for oxalate-
containing foods, which were batched for each subject to minimize
variation in oxalate content for the duration of study. All meals were
prepared in the Mayo Clinic Clinical Research Unit. Subjects received
the morning meal in the clinical research unit, and were given the
noon and dinner meal to take home. All calcium supplements were
held for this period. A 4-day run-in period on the controlled
metabolic diet is required to achieve steady-state status in relation to
calcium balance and sodium balance.45 After 4 days on the controlled
metabolic diet, two initial 24-h urines were collected on consecutive
days (days 5–6; time zero urine collections). Subjects then took of the
following regimens: (1) the study preparation (Oxadrop one packet
q.d. plus one placebo capsule b.i.d.; (2) AKSB one capsule b.i.d. plus
one placebo packet q.d.; (3) one placebo packet q.d. and one placebo
capsule b.i.d.). Subjects were instructed to avoid high-oxalate foods
and live culture dairy products (for example, yogurt) between
controlled metabolic diet phases. At the end of the fourth week, the
subjects were placed on the identical controlled metabolic diet. After
4 days, two repeat 24-h urines were collected (days 5–6 back on the
controlled metabolic diet; final urine collections). Final urine oxalate
values were compared with the time zero numbers.
Urine chemistries
Urinary concentrations (24 h) of oxalate, calcium, and other
determinants of SS were measured in the Mayo Clinic Renal Testing
Laboratory. Urine oxalate was measured by oxalate oxidase. SS was
calculated using the EQUIL2 program.46
Stool cultures
When possible, stool samples were collected at the time of urine
collections during weeks 1 and 5 of the study (successful in 33 of 44
subjects). Quantitative stool cultures for lactobacilli, enterococci,
and yeast were performed by technicians at Agri-King, and were
performed blinded to the study identifiers.
Statistics
Differences between baseline and time zero urine values were
evaluated by the paired t-test and signed-rank tests. Treatment
group differences (AKSB, Oxadrop, and Placebo) were compared
using the Kruskal–Wallis test. Bivariate Spearman’s rank correlation
was used to test the linear association between urinary CaOx SS and
the urinary composition (urinary oxalate, volume, calcium, and
citrate) after pooling all readings (baseline and time zero). Multiple
linear regression analysis was used to identify independent
predictors of CaOx SS, with generalized estimating equations
models employed to adjust for potential lack of independence
(using an exchangeable correlation structure). The primary out-
comes were changes in urinary oxalate and CaOx SS between the
time zero and final urine collections. All reported P-values were two-
sided, and Po0.05 was considered statistically significant. With a
minimum of 14 persons per group, we had 80% power to detect a
change in urine oxalate of 0.11 mmol/l/day and in CaOx SS of 0.66
DG. Statistical analyses were performed using SAS software, version
9.1 (SAS Institute, www.sas.com).
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Figure 3 | Study design. Baseline urine collections to qualify for the study were collected on a free-choice diet. Patients were placed
on a controlled metabolic diet on the first and last week of the study. Two time zero 24-h urine samples were collected on days 5 and 6
of the first week on the controlled metabolic diet (time zero urines) before study preparation was initiated. The probiotic or placebo was
then administered for 4 weeks (weeks 2–5). Patients were next placed back on the controlled metabolic diet for the final week of the study
(week 5), with two more final urine sample collections on days 5 and 6 of that week (final urines).
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